Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Anlon Healthcare Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹91
Per ShareLot Size
164 Shares
Minimum Investment
₹14,924
Issue Size
₹121.03 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
10%
QIB Quota
75%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
70.26%
Promoter Holding (Post-Issue)
52.68%
Issue Type
Book Building
ISIN
INE0Y8W01025
We are a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates ("Pharma Intermediate") which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients ("APIs") which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula ("FDF") such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Our products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. Our active pharmaceutical ingredient products are manufactured in accordance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, USP. We face competitions from various listed peers including Kronox Labscience Limited, AMI Organics Limited, Supriya Lifescience Limited, etc.
Revenue, profit after tax and total assets across the last 2 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of up to 1,33,00,000 equity shares of face value of Rs.10/- each ("equity shares") of Anlon Healthcare Limited ("the company" or the "issuer") for cash at a price of Rs.91/- per equity share (including a securities premium of Rs.81/- per equity share) ("issue price") aggregating up to Rs. 121.03 crores ("the issue"). The issue will constitute 25.02% of the post-issue paid-up equity share capital.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
India's strong position in generic drug manufacturing has been a major growth driver for the pharmaceutical industry. With patents expiring on several blockbuster drugs globally, Indian pharmaceutical companies have capitalized on the opportunity to produce and export cost-effective generic alternatives, boosting turnover. The Indian pharmaceutical industry is poised for a major expansion, with the annual revenue turnover in pharmaceutical industry is expected to reach INR 7,327 Bn by FY 2030, growing by a CAGR of 10% during FY 2025-30. Additionally, the pharma companies have been expanding their footprint in global markets. Strategic acquisitions, partnerships, and compliance with international quality standards have enabled Indian firms to increase their exports, thereby enhancing their revenue streams.
Our Company was originally incorporated as 'Anlon Ventures Private Limited', a private limited company under the erstwhile Companies Act, 1956, pursuant to a certificate of incorporation dated November 19, 2013 issued by the RoC. The name of our Company was changed from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited' and a fresh certificate of incorporation dated May 27, 2015 was issued by the RoC. Our Company was subsequently converted to a public limited company and the name of our Company was changed from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited' and a fresh certificate of incorporation dated September 02, 2024, was issued by the RoC.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY25 to FY26.